Microcrystalline cellulose

ApprovedSmall molecule

XXenon Pharmaceuticals Inc.

Microcrystalline cellulose is one of 137 small molecule programs targeting Low back pain. It is currently in Approved.

Indications

Total Trials

Active Trials

136

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Post-Operative DeliriumActive, not recruiting

COVID-19Active, not recruiting

Sickle Cell DiseaseActive, not recruiting

OsteoarthritisActive, not recruiting

FrailtySuspended

Low Back PainPhase 2

Active, not recruiting

Post-Operative DeliriumPhase 2

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Sickle Cell DiseasePhase 1

Active, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

FrailtyPhase 2

Suspended

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Microcrystalline cellulose

XXenon Pharmaceuticals Inc.

Approved

1 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Activella

Eli Lilly

Preclinical

—5

Achromycin V

WWyeth-Lederle Vaccines

Glucocorticoid

1 7

Nadroparin

GSK

Preclinical

1 8

Calcium

Eli Lilly

Preclinical

—9

Blood Taken

HHospices Civils de Lyon

Preclinical

1 10

Exoflo

DDirect Biologics, LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalNot yet recruiting

Study completion

NCT05363514

Clinical

Trials by Indication[1]

Menstrual Pain1 trial

Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain

Completed·RRDC Clinical Pty Ltd·Phase 4·NCT05810116·80 enrolled

Sickle Cell Disease1 trial

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

Terminated·YYale University·Phase 1·NCT03978156·6 enrolled

COVID-191 trial

KAND567 Versus Placebo in Subjects Hospitalized With COVID-19

Terminated·NNovakand Pharma AB·Phase 2·NCT06012565·35 enrolled

Transcranial Magnetic Stimulation1 trial

Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

Completed·XXenon Pharmaceuticals Inc.·Phase 1·NCT03468725·20 enrolled

Effectiveness1 trial

Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms

Completed·RRDC Clinical Pty Ltd·Phase 3·NCT05795816·150 enrolled

12 more indications

Sleep Quality1 trial

Effectiveness of Food-grown Magnesium on Sleep Quality/Quantity

Completed·RRDC Clinical Pty Ltd·Phase 3·NCT05825209·84 enrolled

Low back pain1 trial

Open Label Placebo in the Treatment of Low Back Pain

Completed·HHospital de Egas Moniz·Phase 2·NCT02022124·83 enrolled

Efficacy1 trial

To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI

Completed·VVedic Lifesciences Pvt. Ltd.·Phase 3·NCT04955327·225 enrolled

Oral1 trial

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Completed·XXenon Pharmaceuticals Inc.·Phase 1·NCT03340220·130 enrolled

Sedation1 trial

Oral Versus Intravenous Sedation for Ocular Procedures

Completed·—·Phase 4·NCT03246724·327 enrolled

Depression1 trial

Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

Completed·NNeuralstem Inc.·Phase 1·NCT01520649·26 enrolled

Osteoarthritis1 trial

Study of SI000413 in Knee Osteoarthritis Patients

Unknown status·DDong-A Pharmaceutical Co., Ltd.·Phase 2·NCT01525758·152 enrolled

Heterotopic Ossification1 trial

Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma

Unknown status·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT01744314·150 enrolled

Function1 trial

Curcumin and Function in Older Adults

Completed·UUniversity of Florida·Phase 2/3·NCT03085680·17 enrolled

Post-Operative Delirium1 trial

Ramelteon in the Prevention of Post-operative Delirium

Completed·JJohns Hopkins University·Phase 2·NCT02324153·80 enrolled

Frailty1 trial

A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer

Suspended·UUniversity of Rochester·Phase 2·NCT06068543·118 enrolled

Unspecified2 trials

Low Dose Naltrexone Use in Patients With POTS

Not yet recruiting·UUniversity of Calgary·Phase 4·NCT05363514·80 enrolled

A Phase I Study of GT300 in Healthy Subjects

Unknown status·GGenerian Pharmaceuticals, Inc.·Phase 1·NCT04963855·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Microcrystalline cellulose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Microcrystalline cellulose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Microcrystalline cellulose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xenon Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: XXenon Pharmaceuticals Inc.

Microcrystalline cellulose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Menstrual Pain1 trial

Sickle Cell Disease1 trial

COVID-191 trial

Transcranial Magnetic Stimulation1 trial

Effectiveness1 trial

Sleep Quality1 trial

Low back pain1 trial

Efficacy1 trial

Oral1 trial

Sedation1 trial

Depression1 trial

Osteoarthritis1 trial

Heterotopic Ossification1 trial

Function1 trial

Post-Operative Delirium1 trial

Frailty1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News